What is the starting dose of noradrenaline (norepinephrine) for treating shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Norepinephrine Starting Dose for Shock Treatment

The recommended starting dose of norepinephrine for treating shock is 0.05-0.1 μg/kg/min, which should be titrated by 0.05-0.1 μg/kg/min every 5-15 minutes to achieve a target mean arterial pressure (MAP) ≥65 mmHg. 1

Dosing Guidelines and Administration

Initial Dosing

  • Start at 0.05-0.1 μg/kg/min 1
  • Administer via central venous access when possible
  • Can be safely administered through peripheral venous access or intraosseous route for short periods (up to 3-4 hours) in emergency situations 2

Titration

  • Increase by 0.05-0.1 μg/kg/min every 5-15 minutes 1
  • Titrate to achieve:
    • MAP ≥65 mmHg (primary target)
    • Adequate urine output (≥0.5 mL/kg/hr)
    • Improved tissue perfusion
    • Decreased serum lactate

Maximum Dosing

  • Clinical studies show that doses up to 2.5 ± 2.2 μg/kg/min may be required in severe cases 2
  • Doses above 1 μg/kg/min are associated with mortality rates over 80%, suggesting need for adjunctive therapies 3

Timing of Administration

Early administration of norepinephrine is beneficial for patients with shock:

  • Profound and durable hypotension is an independent factor of increased mortality 4
  • Early norepinephrine administration increases cardiac output and improves microcirculation 4
  • It helps avoid excessive fluid administration and potential fluid overload 4, 5
  • Early administration is associated with higher shock control rates by 6 hours (76.1% vs 48.4%) 6

Refractory Shock Management

When shock is refractory to norepinephrine:

  1. Consider adding vasopressin at a fixed dose of up to 0.03 U/min 1
  2. Vasopressin is particularly useful as it acts on different vascular receptors than α1-adrenergic receptors 4
  3. Epinephrine may be considered as an additional agent, particularly with evidence of myocardial depression 1

Monitoring During Administration

  • Establish arterial line monitoring when using vasopressors 1
  • Monitor:
    • Blood pressure (continuous)
    • Heart rate
    • Urine output
    • Skin perfusion
    • Mental status
    • Lactate clearance
    • Renal and liver function tests 1
  • Watch for adverse effects:
    • Arrhythmias
    • Hypertension (resolves with dose reduction)
    • Tissue ischemia from extravasation

Special Considerations

  • In patients with chronic hypertension, consider targeting a higher MAP 4
  • For profound hypotension (diastolic BP ≤40 mmHg or diastolic shock index ≥3), consider earlier administration of norepinephrine 5
  • Pediatric patients may require higher doses than those suggested in adult literature 2
  • Extravascular administration can result in severe skin injury; phentolamine (0.1-0.2 mg/kg up to 10 mg diluted in 10 mL of 0.9% sodium chloride) injected intradermally at extravasation site may help counteract dermal vasoconstriction 7

Remember that norepinephrine should be administered after or simultaneously with appropriate fluid resuscitation, but prolonged hypotension should not be allowed while waiting for fluid resuscitation to restore blood pressure.

References

Guideline

Vasopressin Use in Shock

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Vasopressors to treat refractory septic shock.

Minerva anestesiologica, 2020

Research

Norepinephrine in septic shock: when and how much?

Current opinion in critical care, 2017

Research

Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial.

American journal of respiratory and critical care medicine, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.